Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + rituximab retreatment for relapsed/refractory chronic lymphocytic leukemia after prior VenR
ACTRN12623000640606Phase 2Terminated
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of venetoclax and rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 cohorts), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Progression-free survival. Started May 2025; status: terminated.
02
Drugs
venetoclaxrituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ACTRN12623000640606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000640606.